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Evidence That Multiple Myeloma Ig Heavy Chain VD J Genes Contain Somatic Mutations But Show No Intraclonal Variation
By Marleen H.C. Bakkus, Carlo Heirman, Ivan Van Riet, Ben Van Camp, and Kris Thielemans
To investigate whether somatic hypermutation occurs in multiple myeloma (MM) lg VH region genes, we have cloned and sequenced the expressed VH genes from five cases of MM. The sequences were obtained after polymerase chain reaction (PCR) on total RNA isolated from the bone marrow, using 5' VH family-specific leader and 3' Cy-or Ca-specific primers. MM-specific CDR3 oligonucleotides were produced to isolate VH genes expressed by the malignant plasma cells. In all five cases, the productive lg gene used the vH3 family. Extensive sequence analysis of multiple independent M13 clones showed no intraclonal variation with no evidence for
HE DIVERSITY of the antibody repertoire is created
T by a number of molecular mechanisms: (1) joining of different variable (V), diversity (D; in heavy chain only), and joining (J) gene segments; (2) junction diversity and N-sequence additions; (3) pairing of heavy and light chains to form a functional protein; and (4) somatic hypermutation throughout the V regions. ' The mechanism of somatic hypermutation is still unknown. There are several observations that indicate that a specific mechanism is involved because: (1) the frequency of somatic mutation (estimated at W3/bp/generation) is too high to be caused by a spontaneous p r o c e s~~,~; and (2) mutations are only found in the rearranged IgV regions and not in the constant regions.4*s
The hypermutation mechanism seems to be activated only at a specific stage in the B-cell differentiation pathway and contributes to the maturation of the Ig repertoire during the late primary and secondary immune response.2 It has been suggested that the process is turned on when B cells enter the memory compartment after stimulation by antigen and that it is active only during avery limited period of time.6-s A shift in the repertoire towards high-affinity antibodies is thus created by a strong selective force that allows amino acid replacements in the complementarity determining regions (CDRs) and suppresses such mutations in the framework regions ( F R S ) .~,~, '~ Most of our understanding of the contribution of somatic mutations to the antibody repertoire comes from animal studies in which the immune response can easily be manipulated. However, in the human system, evidence for so-ongoing somatic hypermutation in MM VH region genes. We were able to identify possible germline counterparts of the expressed VH genes in two cases. Comparison of these genes shows that the MM VH region genes have somatic mutations characteristic for an antigen-driven process. In the other three cases, no close homology could be found with published vH3 sequences. These findings implicate that, in MM, clonal proliferation takes place in a cell type that has already passed through the phase of somatic hypermutation. 0 1992 by The American Society of Hematology.
matic mutations of the expressed Ig genes has been found through the study of follicular non-Hodgkin's lymphoma B cells.1*J2 Studies comparing the sequences of the Ig repertoire, expressed by clonally related tumor cells, have shown the presence of extensive amino acid variability within the hypervariable regions (or CDRs) while silent mutations, not leading to amino acid changes, were observed in the FRs.~'.'~ These data are reminiscent of the observations made during the immune response in experimental animals, and might suggest that the antigen receptor of these malignant B cells is subject to the same control mechanisms or selective forces that preserve the overall structure of their membrane Ig. The elucidation of these selective forces could provide important information about the growth control of these low-grade malignancies. For these reasons, other B-cell malignancies have been studied in an effort to find mutations of their Ig genes. None could be found in B-cell acute lymphocytic leukemia (B-ALL),13 B-cell chronic lymphocytic leukemia (B-CLL; except for a small CD5-subset in which intraclonal diversity has been demonstrated),14-17 or Burkitt's lymphoma.1s We have recently reported serologic evidence (now confirmed by sequencing data, manuscript in preparation) for somatic mutations in hairy cell 1e~kemia.l~ Somatic mutations of the Ig genes have been shown in a few examples of human autoantibodies20-23 and in an anti-idiotype antibody involved in the regulation of the immune response against rabies virus."
We have extended this survey of B-cell malignancies to multiple myeloma (MM). This B-cell neoplasia is characterized by a clonal expansion, mainly in the bone marrow (BM), of malignant plasma cells producing high amounts of IgG or IgA.2s,26 In a number of cases, the antigen specificity of this monoclonal Ig could be determined as an autoantigen. Only a few present specificity for foreign antigen.*' If an antigen would indeed play a role in the expansion of a B-cell clone that develops into MM, one might expect to find somatic mutations in the expressed Ig genes. Moreover, it is suggested that the precursor cells of MM are derived from the memory B-cell If this is the case, one also would expect to find somatic mutations in the differentiated plasma cells.
We have used the polymerase chain reaction (PCR) technique to amplify the tumor VH genes from MM BM samples. We present here the nucleotide sequences of the VDJ genes of two IgA and three IgG myeloma patients.
STRUCTURE OF MULTIPLE MYELOMA VH GENES
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MATERIALS AND METHODS
BM aspirates were obtained from five MM patients. Mononuclear cells (MNC) were isolated from these samples by Ficoll-Hypaque (1.077 kg/L; Pharmacia, Uppsala, Sweden) density centrifugation. The degree of marrow plasmacytosis was defined by immunologic staining for cytoplasmic Ig heavy and light chains as d e s~r i b e d .~~ Table 1 summarizes the clinical and laboratory data of the five patients used in this study.
DNAIRNA isolation. High molecular weight DNA and total RNA were coextracted from the BM cells by a guanidine isothiocyanate method with cesium chloride modification?O Amplification and sequencing of the myeloma CDR3 regions. Total RNA (5 pg) was reverse transcribed using an oligo d(T) primer and the cDNA synthesis kit from BRL (Life Technologies, Ghent, Belgium) in a 5O-kL reaction volume. The first-strand cDNA was drop-dialyzed for 2 hours on a 0.025-pm VS filter (Millipore, Brussels, Belgium) against H20. Amplification was performed in a 50-pL volume containing 10 mmol/L Tris, pH 8.3, 50 mmol/L KCL, 2 mmol/L MgC12, 0.01% (wt/vol) gelatine, 30 pmol of each oligonucleotide primer, 2 mmol/L of each deoxynucleotide triphosphate, 1.25 U Tag polymerase (Cetus Corp, Emeryville, CA) on 1 to 2 pL of the first-strand cDNA reaction materia1.31.32 The first set of primers used (Table 2 ) was a V H -F R~ consensus primer, composed of 21 of the final 27 bases of the sense sequence that encodes the V H -F R~ region, and an isotype-specific antisense primer, either specific for Cy or specific for Ca. The primers were designed to contain a restriction site at their 5' end (EcoRI in the sense primer and BamHI in the antisense primers, the underlined sequences) to allow directional cloning in M13mp18 and M13mp19. Each PCR cycle consisted of 94°C heat denaturation for 0.5 minutes and primer annealing at 60°C for 0.5 minutes, followed by primer extension at 72°C for 1.5 minutes. Forty cycles were performed in a Biomed Thermocycler (Braun, Brussels, Belgium). The first cycle was preceded by a 2-minute denaturation step at 94°C and the last elongation step was prolonged to 10 minutes to ensure full-length products. The amplified DNA was purified by cryoelution. Thirty microliters of the PCR mixture was electrophoresed in a 1% agarose gel. The appropriate band was cut out and placed in a 0.5-mL eppendorf tube punctured centrally at the bottom and containing a nylon wool plug. The tube was incubated for 5 minutes in liquid nitrogen, put into a second eppendorf tube (1.5 mL), and centrifuged for 5 minutes at full speed. The DNA-containing solution in the second tube was phenol/chloroform and chloroform extracted, ethanol precipitated, and digested with EcoRI and BamHI before ligation in linearized MI3 mp18 or MI3 mp19. One-tenth of the ligation mixture was used to transform the Escherichia coli strain DH5aF+ according to Hanahan.33 Plaques were screened with a 32P-labeled JH-specific probe.34 Single-strand DNA was prepared from positive plaques and sequenced using dideoxy chain termination sequencing procedures with 35S a-dATP and S e q~e n a s e~~ (US Biochemicals, Cleveland, OH). In an initial screening, we compared the BM samples. T-tracks from 12 independent plaques. The most frequent sequence was considered to be derived from the malignant plasma cells. Based on the complete sequence, oligonucleotides specific for each myeloma-derived CDR3 region were designed.
Amplijication and sequencing of the myeloma VH genes. VH leader primers specific for the different VH families were used together with Cy or Ca primers to amplify the expressed VH genes in the BM fraction (Table 2) . VH leader primer sequences were kindly provided by V. Pascual (Department of Microbiology, University of Texas, Dallas) and R. Schuurman (University Hospital, Leiden, The Netherlands). All primers were designed to contain an EcoRI site at their 5' end (the underlined sequence). Amplification was performed as described above. The amplification products were electrophoresed in a 1.5% agarose gel, blotted onto Hybond N-plus membranes, and hybridized with the different myeloma-specific CDR3 oligomers that were end-labeled with 32P-y ATP and T4 polynucleotide kinase. Hybridization was performed in 25% formamide, 3 X SSC at 42°C. Membranes were washed at 55°C in 1 x SSC, 0.1% sodium dodecyl sulfate (SDS) and exposed for 2 hours on Kodak XAR film (Eastman Kodak, Rochester, NY). The amplified VH product that hybridized with the patient-derived CDR3 oligomer was processed as above for cloning into M13mp18 and M13mp19. Plaques were screened with the corresponding MM-CDR3 oligomers and V~3-specific probes.36 Double-positive clones were sequenced. All sequences were confirmed by subcloning and sequencing in both orientation.
Genomic DNA (0.5 pg) was amplified using a 3' primer specific for the spacer-nonamer sequence of V H~ germline genes (based on Pascual and Capra3') and a 5' primer specific for the CDRl region of the germline gene VH26, the "mutated" CDRl region of VH-VD, or the v H 3 leader ( Table 2 ). The amplification products were blotted as above and hybridized with a 32P-y ATP end-labeled oligonucleotide, specific for either the germline CDR2 regions of VH26 or HHG19G and the "mutated" CDR2 regions of VD and BO (Table 2) . Hybridization and washing was performed in 3 mol/L tetramethyl ammoniumchloride as described. 38 Final washing temperatures were 3 to 4°C below the Tm. The Tm = -682 (L-l) + 97 in which L is the length of the oligo.
The VH26 germline amplification product was cloned and sequenced as above and compared with the published sequence. 39 To assess the base fidelity of Tag polymerase, 12 independent Isolation ofgermline VHsequences.
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For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From PCR products in M13 phages was performed. Independent recombinant M13 clones were sequenced. We first compared the positions of the thymidine nucleotides in the 12 isolates (so-called T-tracks). The data are summarized in Table 3 . The majority of the T-tracks analyzed were indeed identical and, thus, all derived from the monoclonal population. This was further confirmed by using the same set of primers to amplify the expressed Ig genes from three different samples of normal BM (NBM) samples. We never could find identical sequences in these samples, which validates the assumption that the identical sequences found in the MM BM were derived from the myeloma clone. The other nonidentical T-tracks (2 in patient CA and 3 in patient DA) were different also among themselves, probably representing normal B cells. However, in the case of PI, 7 of the 10 T-tracks analyzed were identical, as were the other 3 clones analyzed. This might indicate that this BM sample contained two monoclonal populations (one major population represented by the 7 identical clones and one minor population represented by the 3 identical T-tracks) or that the monoclonal population expresses two different VDJ sequences, one functional and one nonfunctional. Having determined the tumor-derived M13 clones, we pcrformed the complete sequence of the CDR3 region. From these sequences (Fig 2) we designed patient-spccific CDR3 oligonucleotides (underlined sequences in Fig 2) . The specificity of these oligonucleotides When used as 
JZP-Iabelcd probes to detect tumor derived sequences is
hybridized in a Southem blot experiment to the corresponding tumor DNA and not with any of the control samples.
We then determined to which of the six VH families the tumor Ig belonged by using familyspecific VH leader primers together with the isotypc-specific primers. A major amplification product of about thc expected size (480 bp) was Obtained with the vH3 familyspecific primer in each case ( 
RESULTS
Preparation of myeloma-spc$c CDW proks. Amplification of the CDR3 regions of the expressed Ig genes, VHS-specific primers was used. m e n these agarose gels wefe blotted Onto a nylon membrane and hybridization was rearranged to eithcr cy (BO, PI, and VD) or G (cA and DA) ( Table 2) , resulted in clear distinct bands, which ranged in size from 150 to 190 bp (Fig la, BO not shown) . Thc Cy and Cu primers wcrc tcstcd for their isotype Amplification with the VH-FR3 primer and thc Cy or Cu primcrs showed only an appropriate amplification product smear was observed (Fig la, lanc 3) . representing the size Figure 5 shows the myeloma vH3 sequences, the VH26, and the HHG19G sequence compared with a consensus sequencejVH26 is an example of a germline vH3 gene expressed in the fetal repertoire (30PI),M as well as in an autoantibody with anti-doublestranded (ds) DNA activity (18-2), derived from a patient with systemic lupus erythematosus (SLE)!' To address the question of whether the nucleotide differences between the genes expressed in VD and BO and the germline genes VH26 and HHG19G. respectively, were due to somatic mutation or reflect allelic heterogeneity or the existence of yet unknown V gene elements, we have tried to identify these genes in the vH3 germline repertoire of these patients. We used two approaches. First, we amplified genomic DNA from the BM fraction from patient VD with a 3' primer specific for the spacer-nonamer sequence of vH3 germline genes together with a 5' primer either specific for the germline CDRl sequence of VH26 or specific for 9, and 14) . Vf + 4 (lanes 3, 8,   and 13). V,,3 (lanes 2, 7, and 12).  VH5 (lanes 1,6, and 11 -------------------------------B------------------------------------------------------- .......................................................................................  ..........................................................................................   ----------------------A-------------------------------------------------------------------G---------------------------------------------------------------------------------------- -----------------A------------------------------------------------------------------------ 
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75 TCAAGTATTAGTGGTAGTGGCGGTAGCACATTCTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGGACACA Table 2 ). The quence ( Table 2 ). The hybridization conditions were choresuits are shown in Fig 6. An amplification product of the sen in such a way that we could discriminate between expected size of 242 bp was only observed when the perfectly matched probes and probes with 1 to 2 base VH26-CDR1 primer was used. No such amplification mismatches. Only the VH26-CDR2 probe and the products were detected with the "mutated" VD-CDR1 HHG19G-CDR2 probe hybridized with the germline ampliprimer, indicating that this sequence is not present in the fication products, whereas the "mutated" VD-CDR2 and vH3 germline repertoire of patient VD. The VH26 PCR BO-CDR2 probes only hybridized with the vH3/cy ampliproduct was cloned and sequenced and showed 100% fication products derived from the RNA of these patients. identity with the published sequence. Second, we amplified This finding indicates once more that the VH genes exvH3 germline sequences using the vH3 leader primer pressed in these MM patients are not present in the vH3 together with the 3' vH3 spacer-nonamer primer. The PCR germline repertoire as detected in this assay, but that these was performed on genomic DNA derived from the BM genes probably represent somatically mutated genes. fraction from patient VD, from peripheral blood (PBL)
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Comparison at the nucleotide level of VH26 with VH-VD cells of patient BO, and from granulocytes of an unrelated and of HHG19G and VH-BO showed 16 and 24 base person. Amplification products were of the expected size differences, respectively (Fig 7A) . Comparison of deduced (500 bp). To determine the presence of VH26 and HHG19G amino acid sequences showed that nucleotide differences sequences and, possibly, the VH-VD and the VH-BO seresult in both silent and replacement mutations (Fig 7B) . In quences in these amplified vH3 germline genes, we perthe case of VD, 5 of 7 replacement mutations, but only 1 of formed a Southern blotting experiment using 3*P end-7 silent mutations, reside in or nearby the CDRs. In the labeled probes with specificity for the VH26-CDR2 FRs, this pattern is completely reversed; only 2 of 7 sequence, the HHG19G-CDR2 sequence, the "mutated" replacement mutations and 7 of 8 silent mutations reside in VD-CDR2 sequence, and the "mutated" BO-CDR2 sethe FRs. and only 1 of 7 silent mutations reside in or nearby the CDRs, while 6 of 1 3 replacement and 6 of 7 silent mutations reside in the FRs. Such a nonrandom distribution of silent and replacement mutations in antibody V regions is consistent with a process of somatic mutation and antigen selection.10
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The JH segments present in the five myeloma sequences in comparison with the most homologous germline JH sequences are shown in Fig 8A. Germline sequences are according to Kabat et a14* and adapted to Yamada et a1.43 Differences at the 5' boundary may represent junctional diversity. The other differences might be due to somatic mutation or represent polymorphism of these J segments. In the case of BO and PI, the J H~ sequence was used. In the case of DA, the J H~ sequence was used. In the case of VD, the JH6 sequence was used. In the case of CA, the JH1 sequence was used, which is noteworthy because until now only 2 JH1 sequences had been found." The D segment assignment is shown in Fig 8B. to fuse with different fusion partners has hampered the analysis of the Ig genes in this disease. By using the reversed PCR technique with isotype-specific primers and CDRspecific oligos, it was possible to isolate the tumor VH genes. Most of the amplified CDR3 products from one BM sample showed the same nucleotide sequences expected when amplifying a monoclonal population. Only in the case of PI is it possible that a second clone might be present in the BM, because from the 10 sequences analyzed, 7 were identical, representing the major MM clone, but the remainuse only. ing 3 were also identical to each other. Although the myeloma origin of thesc sequences remains to be proven, this biclonal pattern after amplification was never observed using NBM cells. It is also possible that these two sequences are exprcsscd in a single cell, rcpresenting a functional and a nonfunctional transcript.
The ncccssity to dcsign CDRIspecific oligos to isolate the tumor VH gene is especially clear in the case of DA. In this case, scvcral clear amplification products were obtained with different VH family-specific primer combinations, probably because this BM sample contained more B cells expressing the vH2, 4, or 5 family than the other samples. Hybridization of these products with the MMspecific CDR3 oligos, derived from the first amplification step, was nccessary to prove which of these VH-amplified products was exprcssed by the MM clone. It appeared that all five MM patients used the vH3 family, but because the vH3 is the largest and most heterogeneous family within the use only. -------D--F----------------- None of the base changes appeared more than once in the different M13 clones, which argues against an ongoing somatic mutation process in these MM VH genes. This low number of base differences can be regarded as artifacts due to the amplification, cloning, and sequencing procedure.
VD-VH ----_---_-----_-----------------~-T-L------------~-_------F---------
While searching for germline genes from which these MM VH genes could have originated, we found two possible candidate genes in the EMBL data bank. The gene VH26 was 95% homologous to the VH fragment of VD and the gene HHG19G was 92% homologous to the VH fragment of BO. For the other three MM VH genes, no such homology to known germline VH3 genes could be found, which makes it hard to determine if these genes represent yet unknown germline genes or heavily mutated variants of known VH genes. VH2639 is an example of a germline vH3 gene expressed in the fetal repertoire (30 PI),4o as well as in an autoantibody with anti-ds DNA activity (18-2) derived from a patient with SLE. 40 The HHG19G gene represents a vH3 germline gene (unpublished sequence). Nucleotide sequence comparison suggested that the MM VH genes were somatically mutated forms of these germline vH3 genes. Alternatively, such nucleotide differences could stem from novel members and/or polymorphisms of known members of the vH3 gene family. To discriminate between these alternatives we searched for MM-specific sequences in the patients' germline DNA. No evidence for the presence of MM-specific CDRl and CDR2 sequences in the germline DNA was found. These findings, together with the typical nonrandom distribution pattern of silent and replacement mutations in the MM VH gene fragments when compared with the VH26 and HHG19G genes, strongly suggest that in these MM VH genes a somatic mutation process has taken place, followed by antigen selection.
The absence of intraclonal variations among the MM VH genes studied here is in great contrast with the findings in lymphoma or hairy cell leukemia. Hybridomas derived from lymphoma patients were all different, showing extensive somatic mutations with replacement mutations clustered in the CDRs. This was also the case in hairy cell leukemia, although not as pronounced, with a smaller number of base substitutions and more identical sequences. This may reflect the stage of B-lymphoid development in which the malignant conversion took place. To date, IgV mutations have been localized in a discrete stage of B-cell development, ie, late in the primary response as cells are being chosen for the memory ~o m p a r t m e n t .~~ The malignant counterpart of this stage may be follicular lymphoma, which explains the ongoing somatic mutation in this tumor. Hairy cell leukemia has been considered to reflect a preplasma cell stage that passes through a short phase of somatic mutation followed by a period of selection, rather than being trapped in a continuous mutation pathway, explaining the low number of mutations and the clustering of replacement mutations in the CDRs. MM reflects the most mature phenotype of B-lymphoid development. The finding of no intraclonal variation and no evidence for the genes to be germline encoded suggests that the clonogenic cell in MM is a postgerminal center cell, which can be a memory B cell or plasmablast, that has already gone through the stage of somatic hypermutation and antigen selection. This explains why the major isotype of the paraproteins in MM is IgG or IgA, rather than IgM, and why they reside in the BM. 47 Although it is still possible that the true MM precursor cell, in which the first oncogenic event has taken place, is an earlier cell type. In that case, important selection events must have occurred in the germinal centers that result in a clonal proliferation of only one cell expressing one particular VH gene fragment.
In summary, this study illustrates that MM VH genes represent somatically mutated and antigen-selected genes. No (further) divergency of the expressed MM VH genes occurs during malignant proliferation, indicating that the MM clonogenic cell originates from a B cell that has already passed through the stage of somatic hypermutation and antigen selection.
